# Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

> **NCT01294579** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 49 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **BIOLOGICAL:** Ofatumumab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT01294579
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-17
- **Primary completion:** 2016-12-20
- **Final completion:** 2016-12-20
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01294579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01294579, "Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01294579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*